Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with..
– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with..
Quarterly information report as at the end of March 2024
* Solid sales growth in the first quarter*
* (+17% at..
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global..